Post by Dicot Pharma AB

We’re pleased to share that we have successfully completed the development of LIB-01 as a tablet formulation, and have now initiated manufacturing ahead of our upcoming phase 2b clinical study. Transitioning to a tablet at this stage is a strategically important step — strengthening the regulatory pathway, reducing project risk, and positioning LIB-01 well for future commercial development. With manufacturing now underway, preparations continue for study initiation in the second half of 2026. #LIB01 #clinicalstudies #erectiledysfunction